NCT04416165 Comparison of FDG and FAPI in Patients With Various Types of Cancer
| NCT ID | NCT04416165 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Condition | Tumor, Solid |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2019-10-20 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,000 participants in total. It began in 2019-10-20 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.
Eligibility Criteria
Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04416165 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Tumor, Solid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04416165 currently recruiting?
Yes, NCT04416165 is actively recruiting participants. Contact the research team at wuhua1025@163.com for enrollment information.
Where is the NCT04416165 trial being conducted?
This trial is being conducted at Xiamen, China.
Who is sponsoring the NCT04416165 clinical trial?
NCT04416165 is sponsored by The First Affiliated Hospital of Xiamen University. The trial plans to enroll 3,000 participants.